Last reviewed · How we verify
NCT04691349
CAR-T for r/r Malignant Tumors in Children
EARLY_PHASE1 trial testing CAR-T in CAR-T in 10 participants. Status unknown.
26 January 2021
Quick facts
| Lead sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 27 September 2020 |
| Primary completion | 26 January 2021 |
| Estimated completion | 26 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR-T — full drug profile →
Conditions studied
- CAR-T — all drugs for CAR-T →
- Child, Only — all drugs for Child, Only →
- Malignant Tumor — all drugs for Malignant Tumor →
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd. — full company profile →
Who can join
Adults 3 to 18, any sex, with CAR-T or Child, Only. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a clinical study of CAR-T treatment of patients with relapsed/refractory malignant tumors in children. The purpose is to evaluate the safety and effectiveness of chimeric antigen receptor T cells in the treatment of relapsed/refractory malignant tumors in children.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer.
Rodríguez-Nava C, Ortuño-Pineda C, Illades-Aguiar B, Flores-Alfaro E, et al · · 2023 · cited 45× · PMID 37371712 · DOI 10.3390/biomedicines11061610
Verify or expand the search:
- PubMed search for NCT04691349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR-T
Trials testing the same drug.
- NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
- NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
- NCT07441291 — CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT · Phase 3 · recruiting
- NCT07152210 — Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced C · NA · recruiting
- NCT07152236 — Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors · NA · recruiting
Other recruiting trials for CAR-T
Currently open trials in the same condition.
- NCT06642025 — EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia · EARLY_PHASE1 · recruiting
- NCT07139600 — Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy · active not recruiting
- NCT05024175 — Long-term Follow-up of Subjects Treated With CAR T Cells · recruiting
- NCT05514327 — A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL · NA · recruiting
Other PersonGen BioTherapeutics (Suzhou) Co., Ltd. trials
Trials by the same sponsor.
- NCT07338604 — Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies · EARLY_PHASE1 · recruiting
- NCT07284927 — Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies · Phase 1 · recruiting
- NCT07312630 — Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign · EARLY_PHASE1 · recruiting
- NCT07188610 — PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · Phase 2 · recruiting
- NCT06970951 — Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04691349 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Last refreshed: 11 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04691349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing